Targeting the HLA-E–NKG2A axis in combination with MS-275 enhances NK cell-based immunotherapy against DMG
This study is the first to demonstrate that HDAC inhibition enhances NK cell-mediated cytotoxicity in DMG. Combining HDAC inhibition with NK cell therapy represents a promising therapeutic strategy for treating DMG by targeting NKG2A-HLA-E axis.
Authors
- Zhuang Jiang
- Zhengping Zhuang (ORCID: https://orcid.org/0000-0002-0009-7370)
- Jie Feng (ORCID: https://orcid.org/0000-0001-8047-3999)
- L Z Xie (ORCID: https://orcid.org/0009-0009-9980-9662)
- Nan Ji (ORCID: https://orcid.org/0000-0002-9001-8858)
- Chao Du
- Jinqiu Liu (ORCID: https://orcid.org/0009-0008-5459-5894)
- Shuyu Hao (ORCID: https://orcid.org/0000-0002-4224-9424)
- Tian Li (ORCID: https://orcid.org/0000-0003-3064-335X)
- Yi Wang (ORCID: https://orcid.org/0000-0002-1799-0843)
- Liwei Zhang (ORCID: https://orcid.org/0000-0003-1919-3765)
- Xiaoli Zhang (ORCID: https://orcid.org/0000-0002-7686-6965)
- Zhuonan Pu
- Yuxuan Deng (ORCID: https://orcid.org/0009-0009-9733-6304)
- Yi Chen (ORCID: https://orcid.org/0009-0004-9870-5443)
- Mingxu Yang
Institutions
- National Institutes of Health (US)
- Capital Medical University (CN)
- Beijing Tian Tan Hospital (CN)
- Beijing Institute of Neurosurgery (CN)
- National Cancer Institute (US)
- Center for Cancer Research (US)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-04-29
- DOI
- https://doi.org/10.1186/s13046-025-03390-y
- Citations
- 3
- Primary Topic
- Immune Cell Function and Interaction
- Type
- article
- Field-Weighted Citation Impact
- 2.39